To evaluate the efficacy and safety of drug-eluting bead-transcatheter arterial chemoembolization (DEB-TACE) using 100-300 μm versus 300-500 μm CalliSpheres microspheres (CSMs) for treating multiple hepatocellular carcinoma (HCC) with the largest nodule measuring between 5 and 10 cm.

Eighty-one advanced-stage HCC patients treated by DEB-TACE between January 2017 and March 2020 were retrospectively analyzed. There were 48 patients in the 100-300 μm group and 33 patients in the 300-500 μm group. Treatment response, liver function tests, and complications were compared between the two groups.

At 6 months, the response rates in the 100-300 μm group were higher than those in the 300-500 μm group (P < 0.05). Disease control rates in the 100-300 μm group were higher than those in the 300-500 μm group at 1, 3, and 6 months (P < 0.05). Progression-free survival (PFS) and overall survival (OS) were longer in the 100-300 μm group (P < 0.05). Visual analog score points were higher in the 300-500 μm group (P < 0.05). There were no significant differences in complications between the two groups.

The use of small-diameter CSMs in multiple HCC with the largest nodule size of 5-10 cm provides better treatment response and longer PFS and OS for treating advanced-stage HCC.

The use of small-diameter CSMs in multiple HCC with the largest nodule size of 5-10 cm provides better treatment response and longer PFS and OS for treating advanced-stage HCC.

The background of this study was to explore the success rate and early complications concerning the implantation of totally implantable venous access devices (TIVADs) by percutaneous venipuncture and management strategies for early complications.

This was a retrospective study of 1923 patients who received TIVAD implantation by percutaneous venipuncture (mostly via the supraclavicular route). The percutaneous access sites were internal jugular vein (810 patients; right/left 158/652) or proximal right internal jugular vein, brachiocephalic vein, and proximal subclavian vein (1113 patients). Success rates and early complications related to TIVAD placement techniques were summarized, and strategies for managing complications were also analyzed.

In 627 patients, TIVAD implantation was first performed by interventional radiologists using a “blind” approach relying on anatomical landmarks, having a 91.9% success rate. In contrast, there was a 100% success rate among the remaining 1296 patients who received ulccess rate and reduces the risk of early complications. Unclear anatomical landmarks and vascular variation are the main factors affecting success using a blind (nonguided) technique.

Detection of early-stage lung cancers has increased due to computed tomography (CT). The pathological stages and subtypes of early lung cancer determine the treatment strategy. We aimed to investigate the correlation between CT characteristics and pathological status in early lung adenocarcinoma (ADC).

Between June 2018 and December 2019, 415 consecutive patients who underwent surgery for lung ADC with pathological atypical adenomatous hyperplasia (AAH) and ADC in situ (AIS), T1a (mi) N0M0, and T1a-cN0M0 were analyzed. The relationship between CT imaging and pathological status was investigated using Chi-squared or Kruskal-Wallis test and binary logistic regression.

When cases of AAH, AIS, and T1a (mi) N0M0 were used as the control group, the lesion size, solid component ratio (SCR), and spiculation were significantly and independently associated with T1a-cN0M0 (P < 0.01). SCR >50% (P < 0.01) and spiculation (P < 0.05) were significantly and independently associated with T1aN0M0. In cases of pathological T1a-cN0M0, SCR >50% was significantly different between adherent wall growth ADC and mucinous ADC (P < 0.01).

Some CT characteristics are related to the pathological stage and subtypes of early lung ADC. Larger diameter, spiculation, and SCR >50% are associated with invasive ADC. SCR >50% is positively correlated with mucinous ADC and negatively with adherent growth ADC.

50% is positively correlated with mucinous ADC and negatively with adherent growth ADC.

The objective of the study is to compare computed tomography (CT)-based I

radioactive seed brachytherapy (RSB) joint three-dimensional conformal radiotherapy (3D-CRT) and stereotactic ablative radiotherapy (SBRT) on early nonsmall cell lung cancer (NSCLC).

The study involved 30 Stage I and II NSCLC patients from March 2014 to June 2017. The patients were divided into two groups 20 cases with CT-based RSB-3D-CRT (300 cGy × 10) (Group A) and 10 cases with SBRT (8 cGy × 6) (Group B). Their local control rates, 1-year survival rates, and toxic and side effects were compared.

The median time of follow-up was 20 months (3-51 months). The 1-year local control rate in Groups A and B was 90% and 80%, respectively (P = 0.70). The 1-year survival rate in Groups A and B was 90% and 90%, respectively (P = 1.00). The indicator of radioactive pneumonia V

and V

in Groups A and B was 6.06% and 4.207%, and 11.32% and 7.111%, respectively (P = 0.000024 and 0.00090).

Compared with SBRT, RSB-3D-CRT was more aggressive on early NSCLC. It remarkably reduced the indicators (V

and V

) and the incidence of radioactive pneumonia.

Compared with SBRT, RSB-3D-CRT was more aggressive on early NSCLC. It remarkably reduced the indicators (V20 and V30) and the incidence of radioactive pneumonia.Immune checkpoint blockade with programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) inhibitors has been standard care for metastatic nonsmall cell lung cancer (NSCLC) and after progression using first-line platinum-containing chemotherapy. Molibresib supplier Although several management guidelines exist for immune checkpoint inhibitor-induced toxicities, uncommon, complicated, and life-threatening immune-related adverse events remain challenging for oncologists. In this report, we presented a male patient with NSCLC who received pembrolizumab during disease progression. He developed interstitial pembrolizumab-induced organizing pneumonia (OP). The patient received 9 months of anti-PD-1 pembrolizumab when he presented with dry cough and fatigue. The patient developed a solitary nodular lung lesion mimicking a newly occurred metastatic lesion in the lung without a significant circulating tumor marker increase. Sputum analysis was negative for acid-fast bacilli and fungi. A computed tomography-guided percutaneous lung biopsy was conducted and showed alveolar fibrous thickness and various lymphocyte infiltration.